Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681682 | 0.85 | AOC3 (0.50) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL1742768 | 0.85 | AOC3 (0.50) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL6204864 | 0.83 | L3MBTL1 (0.51) | CASRAOC3ACHEL3MBTL1CA1 | |
| SCHEMBL8053712 | 0.83 | L3MBTL1 (0.51) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL10290007 | 0.83 | CASR (0.53) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL84440 | 0.83 | HDAC4 (0.55) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL11619720 | 0.83 | CASR (0.53) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL30601580 | 0.83 | HDAC4 (0.55) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL11563492 | 0.82 | AOC3 (0.50) | CASRAOC3ACHEL3MBTL1TAAR1 | |
| SCHEMBL6204866 | 0.82 | AOC3 (0.56) | CASRAOC3ACHEL3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026860-A | Preparation method of 3- [1- (dimethylamino) ethyl ] phenol | 福建福瑞明德药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| CN-118026860-A | Preparation method of 3- [1- (dimethylamino) ethyl ] phenol | 福建福瑞明德药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| CN-109661396-B | Spiro-fused cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| EP-2073816-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-101171234-A | Dihydropyridine derivatives | OUGARI CO LTD (NL) | 2008-04-30 | — | — | CN | disclosed |
| CN-1706820-A | Prepn and application of N-[2-(aryloxy)ethyl]-2-(arylthio) benzyl amine derivative | UNIV TIANJIN (CN) | 2005-12-14 | — | — | CN | disclosed |
| EP-0572001-B1 | Furobenzopyran derivatives, process for preparation of same and herbicides containing same as active components | MITSUI CHEMICALS INC (JP) | 1998-08-05 | — | — | EP | disclosed |
| US-5530146-A | TETRAHYDROFURAN DERIVATIVE INTERMEDIATES | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1996-06-25 | — | — | US | disclosed |
| US-5356866-A | Completely selective to crops such as paddy rice, soybeans and cotton | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-10-18 | — | — | US | disclosed |
| EP-0572001-A1 | Furobenzopyran derivatives, process for preparation of same and herbicides containing same as active components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | CASR 3016/4885AOC3 3250/4885ACHE 4667/4885 |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | CASR 4855/4885AOC3 2751/4885ACHE 3612/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | CASR 4518/4885AOC3 4605/4885ACHE 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.